Get the Stockscreener App
0.49
0.14%
-0.0007
Century Therapeutics Inc stock is traded at $0.49, with a volume of 559.61K.
It is down -0.14% in the last 24 hours and down -13.27% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.4907
Open:
$0.49
24h Volume:
559.61K
Relative Volume:
0.61
Market Cap:
$42.78M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.214
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+3.75%
1M Performance:
-13.27%
6M Performance:
-15.46%
1Y Performance:
-60.48%
1-Day Range:
$0.464
$0.4989
1-Week Range:
$0.435
$0.52
52-Week Range:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.49 | 42.84M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What machine learning models say about Century Therapeutics Inc.Dividend Hike & Consistent Income Trade Ideas - newser.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Leerink Partners Reaffirms “Market Perform” Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - Defense World
Take off with Century Therapeutics Inc (IPSC): Get ready for trading - Setenews
What technical signals suggest for Century Therapeutics Inc. stockCPI Data & Accurate Entry and Exit Point Alerts - newser.com
How Century Therapeutics Inc. stock compares to industry benchmarksMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Century Therapeutics Shares Fall After Leerink Partners Downgrade - MarketScreener
IPSC Stock Downgraded by Leerink Partners: Price Target Slashed - GuruFocus
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform, Price Target is $7 - MarketScreener
Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts - Investing.com Canada
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform - MarketScreener
Leerink Partners Downgrades Century Therapeutics (IPSC) - MSN
What Fibonacci levels say about Century Therapeutics Inc. reboundRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Analyzing drawdowns of Century Therapeutics Inc. with statistical toolsQuarterly Market Summary & AI Powered Market Entry Strategies - newser.com
Century Therapeutics Inc. stock trend outlook and recovery pathWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Published on: 2025-11-15 03:30:02 - newser.com
Can volume confirm reversal in Century Therapeutics Inc.2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Century Therapeutics unveils β islet program for type 1 diabetes - BioWorld MedTech
Century Therapeutics Reports Positive Q3 2025 Earnings - TipRanks
Century Therapeutics Inc. stock trendline breakdownPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Century Therapeutics unveils T1D therapy program with immune evasion tech By Investing.com - Investing.com Nigeria
Century Therapeutics Shrinks Costs But Net Loss Widens - Finimize
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes - Investing News Network
Century Therapeutics Q3 net loss widens, despite lower costs - MarketScreener
Century Therapeutics, Inc. SEC 10-Q Report - TradingView
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Century Therapeutics, Inc. Quarterly Earnings Report | IPSC SEC FilingForm 10-Q - Stock Titan
Century Therapeutics unveils T1D therapy program with immune evasion tech - Investing.com
Century Therapeutics Announces Breakthrough Allo-Evasion™ 5.0 iPSC Beta Islet Therapy for Type 1 Diabetes with Plans for IND Submission by 2026 - Quiver Quantitative
Ready to Jump After Recent Trade: Century Therapeutics Inc (IPSC) - Setenews
What does recent volatility data suggest for Century Therapeutics Inc.Stock Surge & Reliable Momentum Entry Alerts - newser.com
Is Century Therapeutics Inc a good long term investmentEconomic Data Impact & Minimal Investment Capital - earlytimes.in
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):